These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
496 related articles for article (PubMed ID: 16554754)
1. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Arron JR; Winslow MM; Polleri A; Chang CP; Wu H; Gao X; Neilson JR; Chen L; Heit JJ; Kim SK; Yamasaki N; Miyakawa T; Francke U; Graef IA; Crabtree GR Nature; 2006 Jun; 441(7093):595-600. PubMed ID: 16554754 [TBL] [Abstract][Full Text] [Related]
2. Increased dosage of DYRK1A and DSCR1 delays neuronal differentiation in neocortical progenitor cells. Kurabayashi N; Sanada K Genes Dev; 2013 Dec; 27(24):2708-21. PubMed ID: 24352425 [TBL] [Abstract][Full Text] [Related]
3. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Baek KH; Zaslavsky A; Lynch RC; Britt C; Okada Y; Siarey RJ; Lensch MW; Park IH; Yoon SS; Minami T; Korenberg JR; Folkman J; Daley GQ; Aird WC; Galdzicki Z; Ryeom S Nature; 2009 Jun; 459(7250):1126-30. PubMed ID: 19458618 [TBL] [Abstract][Full Text] [Related]
4. Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation. Jung MS; Park JH; Ryu YS; Choi SH; Yoon SH; Kwen MY; Oh JY; Song WJ; Chung SH J Biol Chem; 2011 Nov; 286(46):40401-12. PubMed ID: 21965663 [TBL] [Abstract][Full Text] [Related]
5. Cooperation to amplify gene-dosage-imbalance effects. de la Luna S; Estivill X Trends Mol Med; 2006 Oct; 12(10):451-4. PubMed ID: 16919501 [TBL] [Abstract][Full Text] [Related]
6. Down's syndrome: critical genes in a critical region. Epstein CJ Nature; 2006 Jun; 441(7093):582-3. PubMed ID: 16738647 [No Abstract] [Full Text] [Related]
7. [Molecular Mechanism Underlying Abnormal Differentiation of Neural Progenitor Cells in the Developing Down Syndrome Brain]. Kurabayashi N; Sanada K Yakugaku Zasshi; 2017; 137(7):795-800. PubMed ID: 28674289 [TBL] [Abstract][Full Text] [Related]
8. DSCR1 gene expression is dependent on NFATc1 during cardiac valve formation and colocalizes with anomalous organ development in trisomy 16 mice. Lange AW; Molkentin JD; Yutzey KE Dev Biol; 2004 Feb; 266(2):346-60. PubMed ID: 14738882 [TBL] [Abstract][Full Text] [Related]
9. Restoration of DSCR1 to disomy in the trisomy 16 mouse model of Down syndrome does not correct cardiac or craniofacial development anomalies. Lange AW; Rothermel BA; Yutzey KE Dev Dyn; 2005 Jul; 233(3):954-63. PubMed ID: 15906378 [TBL] [Abstract][Full Text] [Related]
10. Trisomy of the Dscr1 gene suppresses early progression of pancreatic intraepithelial neoplasia driven by oncogenic Kras. Lee JC; Shin J; Baek KH Biochem Biophys Res Commun; 2013 Oct; 440(1):50-5. PubMed ID: 24041692 [TBL] [Abstract][Full Text] [Related]
11. Down syndrome critical region-1 is a transcriptional target of nuclear factor of activated T cells-c1 within the endocardium during heart development. Wu H; Kao SC; Barrientos T; Baldwin SH; Olson EN; Crabtree GR; Zhou B; Chang CP J Biol Chem; 2007 Oct; 282(42):30673-9. PubMed ID: 17693409 [TBL] [Abstract][Full Text] [Related]
12. Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome. Granese B; Scala I; Spatuzza C; Valentino A; Coletta M; Vacca RA; De Luca P; Andria G BMC Med Genomics; 2013 Jul; 6():24. PubMed ID: 23830204 [TBL] [Abstract][Full Text] [Related]
14. A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis. Shin J; Lee JC; Baek KH Cancer Lett; 2014 Jan; 342(1):70-81. PubMed ID: 24051307 [TBL] [Abstract][Full Text] [Related]
15. A patient with Down syndrome with a de novo derivative chromosome 21. Cetin Z; Yakut S; Mihci E; Manguoglu AE; Berker S; Keser I; Luleci G Gene; 2012 Oct; 507(2):159-64. PubMed ID: 22827956 [TBL] [Abstract][Full Text] [Related]
16. NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the Down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect. Stefos GC; Soppa U; Dierssen M; Becker W PLoS One; 2013; 8(6):e67470. PubMed ID: 23825664 [TBL] [Abstract][Full Text] [Related]
17. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Reynolds LE; Watson AR; Baker M; Jones TA; D'Amico G; Robinson SD; Joffre C; Garrido-Urbani S; Rodriguez-Manzaneque JC; Martino-Echarri E; Aurrand-Lions M; Sheer D; Dagna-Bricarelli F; Nizetic D; McCabe CJ; Turnell AS; Kermorgant S; Imhof BA; Adams R; Fisher EM; Tybulewicz VL; Hart IR; Hodivala-Dilke KM Nature; 2010 Jun; 465(7299):813-7. PubMed ID: 20535211 [TBL] [Abstract][Full Text] [Related]
18. Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration. Branchi I; Bichler Z; Minghetti L; Delabar JM; Malchiodi-Albedi F; Gonzalez MC; Chettouh Z; Nicolini A; Chabert C; Smith DJ; Rubin EM; Migliore-Samour D; Alleva E J Neuropathol Exp Neurol; 2004 May; 63(5):429-40. PubMed ID: 15198122 [TBL] [Abstract][Full Text] [Related]
19. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Fuentes JJ; Genescà L; Kingsbury TJ; Cunningham KW; Pérez-Riba M; Estivill X; de la Luna S Hum Mol Genet; 2000 Jul; 9(11):1681-90. PubMed ID: 10861295 [TBL] [Abstract][Full Text] [Related]
20. Regulation of Down Syndrome Critical Region 1 expression by Nuclear Factor of Activated T cells in megakaryocytes. Kyttälä S; Habermann I; Minami T; Ehninger G; Kiani A Br J Haematol; 2009 Feb; 144(3):395-408. PubMed ID: 19036088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]